Bagas Adhimurda Marsudi

Bagas Adhimurda Marsudi

Auto-generated profile, based on publicly available information

Bagas Adhimurda Marsudi

Department of Cardiology and Vascular Medicine, National Cardiovascular Center Harapan Kita, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Microvascular Research
Verified
Journal Article
Closed access
AAAndrianto Andrianto
Andrianto Andrianto
MAMakhyan Jibril Al-Farabi
Makhyan Jibril Al-Farabi
RNRicardo Adrian Nugraha
Ricardo Adrian Nugraha
BMBagas Adhimurda Marsudi
Bagas Adhimurda Marsudi
YAYusuf Azmi
Yusuf Azmi

26 January 2021 in medRxiv
Verified
Preprint
Open access
PDF file
AAAndrianto Andrianto
Andrianto Andrianto
MAMakhyan Jibril Al-Farabi
Makhyan Jibril Al-Farabi
RNRicardo Adrian Nugraha
Ricardo Adrian Nugraha
BMBagas Adhimurda Marsudi
Bagas Adhimurda Marsudi
YAYusuf Azmi
Yusuf Azmi
Background: Several studies have reported that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can directly infect endothelial cells, and endothelial dysfunction is often found in severe cases of coronavirus disease 2019 (COVID-19). To better understand the pathological mechanisms underlying endothelial dysfunction in COVID-19-associated coagulopathy, we conducted a systematic review and meta-analysis to assess biomarkers of endothelial cells in patients with COVID-19. Methods: A literature search was conducted on online databases for observational studies evaluating biomarkers of endothelial dysfunction and composite poor outcomes in COVID-19 patients. Results: A total of 1187 patients from 17 studies were included in this analysis. The estimated pooled means for von Willebrand Factor (VWF) antigen levels in COVID-19 patients was higher compared to healthy control (306.42 [95% confidence interval (CI) 291.37-321.48], p<0.001; I 2 :86%), with the highest VWF antigen levels was found in deceased COVID-19 patients (448.57 [95% CI 407.20-489.93], p<0.001; I 2 :0%). Meta-analysis showed that higher plasma levels of VWF antigen, tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor-1 antigen (PAI-1) antigen, and soluble thrombomodulin (sTM) were associated with composite poor outcome in COVID-19 patients ([standardized mean difference (SMD) 0.74 [0.33-1.16], p<0.001; I 2 :80.4%], [SMD 0.55 [0.19-0.92], p=0.003; I 2 :6.4%], [SMD 0.33 [0.04-0.62], p=0.025; I 2 :7.9%], and [SMD 0.55 [0.10-0.99], p=0.015; I 2 :23.6%], respectively). Conclusion: The estimated pooled means shows increased levels of VWF antigen in COVID-19 patients. Several biomarkers of endothelial dysfunction, including VFW antigen, t-PA, PAI-1, and sTM, are significantly associated with increased composite poor outcome in patients with COVID-19. PROSPERO registration number: CRD42021228821